This document provides guidance on assessing and managing patients with suspected soft tissue or bone sarcomas. It outlines the aims, objectives, and key points including:
- Symptoms and signs to look for during clinical assessment
- Initial investigations and management steps
- Referral criteria for the 2 week wait cancer referral pathway
- An overview of the current patient pathway and areas for potential improvement
Melanoma Prevention, Detection, and Treatment - 5.17.18 - Dr. Eric Huang and ...Summit Health
Sun safety needs to start at an early age in order to reduce the risk for skin cancer. Learn from Summit Medical Group MD Anderson Cancer Center specialists about prevention and ways to reduce your risk, diagnosis and innovations in skin cancer treatments.
Field of oncology has evolved since many decades! This presentation will demonstrate how oncology had evolved. Special focus is on current radiation oncology and surgical oncology practices along with principles of oncology.
Melanoma Prevention, Detection, and Treatment - 5.17.18 - Dr. Eric Huang and ...Summit Health
Sun safety needs to start at an early age in order to reduce the risk for skin cancer. Learn from Summit Medical Group MD Anderson Cancer Center specialists about prevention and ways to reduce your risk, diagnosis and innovations in skin cancer treatments.
Field of oncology has evolved since many decades! This presentation will demonstrate how oncology had evolved. Special focus is on current radiation oncology and surgical oncology practices along with principles of oncology.
CCSN welcomed back Helene Hutchings to discuss anal and colorectal cancer in this educational webinar. Helene discussed the symptoms & risk factors of these cancers, as well as treatment options that are available.
She also discussed prevention of anal and colorectal cancers and the benefits of peer-to-peer support groups.
Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sar...i3 Health
i3 Health is pleased to make the Clinical Decision Aid from this activity available for use as a non-accredited self-study or teaching resource.
Gain insights and perspectives from this multidisciplinary panel of experts as they discuss cases and explore strategies to optimize treatment outcomes for patients with advanced soft tissue sarcoma. This distinguished Virtual Tumor Board features Shreyaskumar R. Patel, MD, Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center; Kathleen Polson, NP, Nurse Practitioner at Dana-Farber Cancer Institute; and Brian Rubin, MD, PhD, Professor of Pathology at Cleveland Clinic Cancer Center
STATEMENT OF NEED
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the identification of genetic alterations in soft tissue sarcoma has led to the rise of targeted therapy, significantly expanding the therapeutic landscape. Remaining up to date on pathological characteristics and emerging data on novel therapies is crucial (Riskjell et al, 2023; NCI, 2023). In this Virtual Tumor Board, Shreyaskumar R. Patel, MD, Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center; Kathleen Polson, NP, Nurse Practitioner at Dana-Farber Cancer Institute; and Brian Rubin, MD, PhD, Professor of Pathology at Cleveland Clinic Cancer Center, will present cases and explore multidisciplinary strategies to optimize treatment outcomes for patients with advanced soft tissue sarcoma.
TARGET AUDIENCE
Medical/surgical/radiation oncologists, pathologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with soft tissue sarcoma.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to
Distinguish patient and tumor characteristics that can inform personalized therapeutic approaches in soft tissue sarcoma
Evaluate emerging data on novel therapies for soft tissue sarcoma
Appraise multidisciplinary strategies to optimize treatment outcomes of patients with advanced soft tissue sarcoma
FACULTY
Shreyaskumar R. Patel, MD
Robert R. Herring Distinguished Professor of Medicine
Center Medical Director, Sarcoma Center
The University of Texas
MD Anderson Cancer Center
Kathleen Polson, NP
Nurse Practitioner
Dana-Farber Cancer Institute
Brian Rubin, MD, PhD
Professor of Pathology
Chairman, Robert J. Tomsich Pathology and Laboratory Medicine Institute
Cleveland Clinic Cancer Center
For Colorectal Cancer Awareness Month, CCSN welcomed back Helene Hutchings to discuss anal and colorectal cancer in this educational webinar. Helene discussed the symptoms & risk factors of these cancers, as well as treatment options that are available.
She also discussed prevention of anal and colorectal cancers and the benefits of peer-to-peer support groups.
There was a Q&A session following the webinar.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Understanding colorectal and anal cancer, including symptoms, risk factors
● Treatment options, including chemotherapy, radiation and biologics
● Preventing colorectal and anal cancer
View the video: https://youtu.be/q0z8N1_L-JQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
CCSN welcomed back Helene Hutchings to discuss anal and colorectal cancer in this educational webinar. Helene discussed the symptoms & risk factors of these cancers, as well as treatment options that are available.
She also discussed prevention of anal and colorectal cancers and the benefits of peer-to-peer support groups.
Virtual Tumor Board: Multidisciplinary Management of Advanced Soft Tissue Sar...i3 Health
i3 Health is pleased to make the Clinical Decision Aid from this activity available for use as a non-accredited self-study or teaching resource.
Gain insights and perspectives from this multidisciplinary panel of experts as they discuss cases and explore strategies to optimize treatment outcomes for patients with advanced soft tissue sarcoma. This distinguished Virtual Tumor Board features Shreyaskumar R. Patel, MD, Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center; Kathleen Polson, NP, Nurse Practitioner at Dana-Farber Cancer Institute; and Brian Rubin, MD, PhD, Professor of Pathology at Cleveland Clinic Cancer Center
STATEMENT OF NEED
Sarcomas, which represent 1% to 2% of adult cancers, are a rare, heterogeneous group of neoplasms originating in the connective tissue. Soft tissue sarcomas, which begin in the muscle, tendons, fat, lymph, blood vessels, and nerves, encompass more than 80 histological subtypes. Approximately 25% of patients develop metastatic disease after curative-intent surgery, and for these patients, treatment options are limited and prognosis is very poor. In recent decades, the identification of genetic alterations in soft tissue sarcoma has led to the rise of targeted therapy, significantly expanding the therapeutic landscape. Remaining up to date on pathological characteristics and emerging data on novel therapies is crucial (Riskjell et al, 2023; NCI, 2023). In this Virtual Tumor Board, Shreyaskumar R. Patel, MD, Medical Director of the Sarcoma Center at the University of Texas MD Anderson Cancer Center; Kathleen Polson, NP, Nurse Practitioner at Dana-Farber Cancer Institute; and Brian Rubin, MD, PhD, Professor of Pathology at Cleveland Clinic Cancer Center, will present cases and explore multidisciplinary strategies to optimize treatment outcomes for patients with advanced soft tissue sarcoma.
TARGET AUDIENCE
Medical/surgical/radiation oncologists, pathologists, nurse practitioners, physician assistants, oncology nurses, and other health care professionals involved in the treatment of patients with soft tissue sarcoma.
LEARNING OBJECTIVES
Upon completion of this activity, participants should be able to
Distinguish patient and tumor characteristics that can inform personalized therapeutic approaches in soft tissue sarcoma
Evaluate emerging data on novel therapies for soft tissue sarcoma
Appraise multidisciplinary strategies to optimize treatment outcomes of patients with advanced soft tissue sarcoma
FACULTY
Shreyaskumar R. Patel, MD
Robert R. Herring Distinguished Professor of Medicine
Center Medical Director, Sarcoma Center
The University of Texas
MD Anderson Cancer Center
Kathleen Polson, NP
Nurse Practitioner
Dana-Farber Cancer Institute
Brian Rubin, MD, PhD
Professor of Pathology
Chairman, Robert J. Tomsich Pathology and Laboratory Medicine Institute
Cleveland Clinic Cancer Center
For Colorectal Cancer Awareness Month, CCSN welcomed back Helene Hutchings to discuss anal and colorectal cancer in this educational webinar. Helene discussed the symptoms & risk factors of these cancers, as well as treatment options that are available.
She also discussed prevention of anal and colorectal cancers and the benefits of peer-to-peer support groups.
There was a Q&A session following the webinar.
Please share this video with anyone who may be interested!
Watch all our webinars: https://www.youtube.com/playlist?list=PL4dDQscmFYu_ezxuxnAE61hx4JlqAKXpR
In this webinar:
● Understanding colorectal and anal cancer, including symptoms, risk factors
● Treatment options, including chemotherapy, radiation and biologics
● Preventing colorectal and anal cancer
View the video: https://youtu.be/q0z8N1_L-JQ
Follow our social media accounts:
Twitter - https://twitter.com/survivornetca
Facebook - https://www.facebook.com/CanadianSurvivorNet
Pinterest - https://www.pinterest.com/survivornetwork
YouTube - https://www.youtube.com/user/Survivornetca
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Model Attribute Check Company Auto PropertyCeline George
In Odoo, the multi-company feature allows you to manage multiple companies within a single Odoo database instance. Each company can have its own configurations while still sharing common resources such as products, customers, and suppliers.
The Indian economy is classified into different sectors to simplify the analysis and understanding of economic activities. For Class 10, it's essential to grasp the sectors of the Indian economy, understand their characteristics, and recognize their importance. This guide will provide detailed notes on the Sectors of the Indian Economy Class 10, using specific long-tail keywords to enhance comprehension.
For more information, visit-www.vavaclasses.com
This is a presentation by Dada Robert in a Your Skill Boost masterclass organised by the Excellence Foundation for South Sudan (EFSS) on Saturday, the 25th and Sunday, the 26th of May 2024.
He discussed the concept of quality improvement, emphasizing its applicability to various aspects of life, including personal, project, and program improvements. He defined quality as doing the right thing at the right time in the right way to achieve the best possible results and discussed the concept of the "gap" between what we know and what we do, and how this gap represents the areas we need to improve. He explained the scientific approach to quality improvement, which involves systematic performance analysis, testing and learning, and implementing change ideas. He also highlighted the importance of client focus and a team approach to quality improvement.
Synthetic Fiber Construction in lab .pptxPavel ( NSTU)
Synthetic fiber production is a fascinating and complex field that blends chemistry, engineering, and environmental science. By understanding these aspects, students can gain a comprehensive view of synthetic fiber production, its impact on society and the environment, and the potential for future innovations. Synthetic fibers play a crucial role in modern society, impacting various aspects of daily life, industry, and the environment. ynthetic fibers are integral to modern life, offering a range of benefits from cost-effectiveness and versatility to innovative applications and performance characteristics. While they pose environmental challenges, ongoing research and development aim to create more sustainable and eco-friendly alternatives. Understanding the importance of synthetic fibers helps in appreciating their role in the economy, industry, and daily life, while also emphasizing the need for sustainable practices and innovation.
4. Must Read
Greater Manchester Cancer
• NICE Sarcoma Guidelines
• Familiarity with 2WW local referral form
• Sarcoma UK
• Bone Cancer Research UK
5. Introduction
Greater Manchester Cancer
A rare type of cancer arising from
mesenchymal/connective tissue
Soft Tissue, Bone or GIST
1% of all primary cancer
Approx 5300 per year (15/day)
100 different sub-types.
5 year survival rate for sarcoma is 55%
6. Sarcoma
Greater Manchester Cancer
• 40-60 years, young adults, children
• No significant aetiology
• Associations: HIV / Kaposis, Neurofibromatosis,
other cancers – 2nd hit hypothesis
• 50% extremities: LL > UL
• Other: Retroperitoneal, Chest, Gynae, Breast
7. World Health Organization classification of
tumours
Tumours are classified by differentiation and biological behaviour.
• Adipocytic tumours
• Fibroblastic/myofibroblastic tumours
• So-called fibrohistiocytic tumours
• Smooth-muscle tumours
• Skeletal muscle tumours
• Vascular tumours
• Chondro-osseous tumours
• Gastrointestinal stromal tumours
• Nerve sheath tumours
• Tumours of uncertain differentiation
• Undifferentiated/unclassified sarcomas.
11. Approach to Patient with a lump
History:
• How long
• Painful
• Increasing in size
• Bigger than 5cm?
• Previous surgery/Rxt
• Discharge or skin changes
• FHx – other cancers: melanoma, lymphoma, lung
• Ask what has been done: other GP, hospital, private
Greater Manchester Cancer
12. Symptoms & Signs
Symptoms
• Pain
• Stiffness
• Local effects
• Non weight bearing
• Vague symptoms
Signs
• Noticeable lump
• Joint swelling
• Skin changes
• Fungating tumour
Greater Manchester Cancer
14. Greater Manchester Cancer
Clinical Examination
• Look: skin changes, naevi, neurofibromas,
multiple lumps
• Feel/Move:
• Location – limb, trunk, areas of lymph nodes?
• Soft or hard
• Mobile or adherent to deeper structures
• Size >5cm?
• Pain
• Joint function
• Neurological symptoms
16. Greater Manchester Cancer
WHOOPS
• Do NOT not biopsy
• Do NOT excise without imaging and discussion
• If in-advertent incision – biopsy and close
17. 2WW Referral Criteria
Greater Manchester Cancer
Lump increasing in size, deep, bigger than 5cm
Painful, fungating, previous surgery, Rxt
Bone changes on Xray
19. Greater Manchester Cancer
Sarcoma Service
• Clinical assessment
• Imaging
• Biopsy: Core biospy. No role for FNA
• Histopathology
• MDT review locally
• Regional MDT
• Management Plan
20. Greater Manchester Cancer
Treatment
• Surgical Excision: Marginal, Wide, Amputation
• Pre or Post op Radiotherapy
• Chemotherapy
• Palliative treatment
21. Greater Manchester Cancer
Pitfalls in patient pathway
• Delayed referral – biggest cause of litigation
• Patients referred to non-tumour specialists
• Poor knowledge of tumours and clinical skills
• WHOOPS
• Where are the scans? Urgent? 2WW?
• Beware the persistent haematoma
• Not taking a history
23. Current Patient Pathway
Greater Manchester Cancer
Clinic and/or MDT < 2 weeks
Biopsy < 2 weeks
Results and MDT 2-3 weeks
Back to Clinic
Total = Min 6 weeks
25. Doctor, I have got a lump, what do I
do with it?
Greater Manchester Cancer
• History: how long, is it getting bigger and painful
• Examine to see is it soft, hard, mobile and deep;
joint swelling – Xrays?
• Refer to local sarcoma service if meets criteria
• Discuss/refer if concerned
Its not a pathway for: Unknown malignancy, get seen quicker, small benign proven
lumps
